Article: Stiefel Laboratories and Grupo Uriach Enter Licensing Agreement for Innovative Molecule.

Investigational Agent, UR-9825 (albaconazole), a broad-spectrum antifungal, for oral and topical administration in dermatology and other indications

Deal is largest in Stiefel's history, Potential for billion dollars in sales

CORAL GABLES, Fla., and BARCELONA, Spain, Sept. 21 /PRNewswire/ -- Stiefel Laboratories, the world's largest privately held company specializing in dermatology and Grupo Uriach, a Spanish pharmaceutical company focused on drug discovery and early drug development, announced today that they have entered into a licensing agreement to develop and market a new chemical entity, UR- 9825 (albaconazole), an oral broad spectrum antifungal ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!